Efficacy and safety of low‐dose otelixizumab anti‐CD3 monoclonal antibody in preserving C‐peptide secretion in adolescent type 1 diabetes: DEFEND‐2, a randomized,placebo‐controlled,double‐blind,multi‐centre study |
| |
| Authors: | P Ambery T W Donner N Biswas J Donaldson J Parkin C M Dayan |
| |
| Institution: | 1. GlaxoSmithKline, , Uxbridge, UK;2. Division of Endocrinology, Johns Hopkins University School of Medicine, , Baltimore, MD, USA;3. Diabetes Research Group, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, , Cardiff, UK |
| |
| Abstract: | |
| |
| Keywords: | |
|
|
